Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 6

Cognitive behavioral therapy for insomnia comorbid with COPD is feasible with preliminary evidence of positive sleep and fatigue effects

Authors Kapella MC, Herdegen JJ, Perlis ML, Shaver JL, Larson JL, Law JA, Carley DW

Published 24 November 2011 Volume 2011:6 Pages 625—635

DOI https://dx.doi.org/10.2147/COPD.S24858

Review by Single-blind

Peer reviewer comments 2

Mary C Kapella1, James J Herdegen2, Michael L Perlis3, Joan L Shaver4, Janet L Larson5, Julie A Law2, David W Carley1
1
Center for Narcolepsy, Sleep and Health Research, Department of Biobehavioral Science, College of Nursing, 2Section of Pulmonary, Critical Care, Sleep and Allergy, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA; 3Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; 4College of Nursing, University of Arizona, Tucson, AZ, USA; 5Division of Acute, Critical and Long Term Care Programs, University of Michigan School of Nursing, Ann Arbor, MI, USA

Background: Many people with COPD report difficulties falling asleep or staying asleep, insufficient sleep duration, or nonrestorative sleep. Cognitive behavioral therapy for insomnia (CBT-I) has proved effective not only in people with primary insomnia but also in people with insomnia comorbid with psychiatric and medical illness (eg, depression, cancer, and chronic pain). However, CBT-I has rarely been tested in those with COPD who have disease-related features that interfere with sleep and may lessen the effectiveness of such therapies. The purpose of this study was to determine the feasibility of applying a CBT-I intervention for people with COPD and to assess the impact of CBT-I on insomnia severity and sleep-related outcomes, fatigue, mood, and daytime functioning.
Methods: The study had two phases. In Phase 1, a 6-weekly session CBT-I intervention protocol in participants with COPD was assessed to examine feasibility and acceptability. Phase 2 was a small trial utilizing a prospective two-group pre- and post-test design with random assignment to the six-session CBT-I or a six-session wellness education (WE) program to determine the effects of each intervention, with both interventions being provided by a nurse behavioral sleep medicine specialist.
Results: Fourteen participants (five in Phase 1 and nine in Phase 2) completed six sessions of CBT-I and nine participants completed six sessions of WE. Participants indicated that both interventions were acceptable. Significant positive treatment-related effects of the CBT-I intervention were noted for insomnia severity (P = 0.000), global sleep quality (P = 0.002), wake after sleep onset (P = 0.03), sleep efficiency (P = 0.02), fatigue (P = 0.005), and beliefs and attitudes about sleep (P = 0.000). Significant positive effects were noted for depressed mood after WE (P = 0.005).
Conclusion: Results suggest that using CBT-I in COPD is feasible and the outcomes compare favorably with those obtained in older adults with insomnia in the context of other chronic illnesses.

Keywords: CBT-I, emphysema, chronic bronchitis, sleep disturbance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Nanostructured lipid carrier surface modified with Eudragit RS 100 and its potential ophthalmic functions

Zhang W, Li X, Ye T, Chen F, Yu S, Chen J, Yang X, Yang N, Zhang J, Liu J, Pan W, Kong J

International Journal of Nanomedicine 2014, 9:4305-4315

Published Date: 11 September 2014

Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims

Mapel DW, Dalal AA, Blanchette CM, Petersen H, Ferguson GT

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:573-581

Published Date: 9 November 2011

Factors associated with good self-rated health and quality of life in subjects with self-reported COPD

Arne M, Lundin F, Boman G, Janson C, Janson S, Emtner M

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:511-519

Published Date: 7 October 2011

Disability related to COPD tool (DIRECT): towards an assessment of COPD-related disability in routine practice

Aguilaniu B, Gonzalez-Bermejo J, Regnault A, Dias Barbosa C, Arnould B, Mueser M, Granet G, Bonnefoy M, Similowski T

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:387-398

Published Date: 5 July 2011

Corrigendum

Seemungal TA, Lun JC, Davis G, Neblett C, Chinyepi N, Dookhan C, Drakes S, Mandeville E, Nana F, Setlhake S, King CP, Pinto Pereira L, Delisle J, Wilkinson TM, Wedzicha JA

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:385-386

Published Date: 4 July 2011

Comparison of efficacy of long-acting bronchodilators in emphysema dominant and emphysema nondominant chronic obstructive pulmonary disease

Fujimoto K, Kitaguchi Y, Kanda S, Urushihata K, Hanaoka M, Kubo K

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:219-227

Published Date: 1 April 2011

New therapeutic options in the management of COPD – focus on roflumilast

Sabina Antonela Antoniu

International Journal of Chronic Obstructive Pulmonary Disease 2011, 6:147-155

Published Date: 17 February 2011